Related Experiment Video

Updated: Sep 21, 2026

Determination of the Relative Cell Surface and Total Expression of Recombinant Ion Channels Using Flow Cytometry
11:32

Determination of the Relative Cell Surface and Total Expression of Recombinant Ion Channels Using Flow Cytometry

Published on: September 28, 2016

Vulnerable substrate and multiple ion channel disorder in a diseased heart will be new targets for antiarrhythmic

D Z Dai1

  • 1Research Division of Pharmacology, China Pharmaceutical University, Nanjing 210009, China. njpdaidz@jlonline.com

Acta Pharmacologica Sinica
|April 28, 2001
PubMed

Insights

Life-threatening cardiac arrhythmias are a major cause of death. New research identifies vulnerable substrate and ion channel disorders as key targets for treating arrhythmias in diseased hearts, offering hope for improved therapies.

Area of Science:

  • Cardiovascular Pathophysiology
  • Molecular Cardiology
  • Pharmacology

Background:

  • Life-threatening arrhythmias contribute significantly to cardiovascular disease mortality.
  • Current antiarrhythmic drugs (AAD) are limited by toxic effects and increased mortality, particularly in diseased hearts.
  • A vulnerable substrate (VS) characterized by reduced NE and SOD activity, myocardial hypertrophy, and increased QT dispersion is implicated in arrhythmia development.

Purpose of the Study:

  • To investigate the role of vulnerable substrate and ion channel disorders in acquired cardiac arrhythmias.
  • To differentiate ion channel abnormalities in congenital long QT syndrome (LQTS) versus acquired heart disease.
  • To identify novel therapeutic targets for managing cardiac arrhythmias in diseased hearts.

Main Methods:

  • Utilized a levothyroxine-induced model to create hypertrophied ventricles and cardiac arrhythmias, mimicking VS properties.
  • Compared ion channel patterns in congenital LQTS with those in acquired heart disease.
  • Investigated the influence of VS lesions on lipid membranes in diseased hearts.

Main Results:

  • The levothyroxine model demonstrated hypertrophied ventricles and exaggerated cardiac arrhythmias, sharing properties with VS.
  • Congenital LQTS involves a single disordered ion channel (e.g., IKr due to HERG gene mutation), while acquired heart disease exhibits multi-channel, non-specific disorders in hypertrophied myocardium.
  • Disordered ion channels are a consequence of VS lesions affecting the lipid membrane in diseased hearts.

Conclusions:

  • Vulnerable substrate and multi-channel ion channel disorders represent novel therapeutic targets for treating cardiac arrhythmias in diseased hearts.
  • Understanding the distinct ion channel abnormalities in congenital versus acquired heart conditions is crucial for targeted therapies.
  • The lipid membrane's role in mediating ion channel dysfunction within the VS warrants further investigation for antiarrhythmic drug development.

More Related Videos

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...